The Role of Sacubitril/Valsartan in Post-acute Myocardial Infarction

Status Completed

Clinical Trial Summary

Sacubitril/Valsartan (SAC/VAL) is a new treatment of congestive heart failure (CHF) recently indicated as class I, level of evidence B in the recent European Society of Cardiology (ESC) guidelines 2016 of CHF. PARADIGM-HF trial demonstrated a significant improvement of morbidity and mortality with SAC/VAL in comparison to enalapril. So far, no data available about the effect of usage of SAC/VAL post-acute myocardial infarction (AMI) except in animal experimental models. The purpose of the research is evaluation of the effects of SAC/VAL in post-AMI in comparison to the traditional Angiotensin Converting Enzyme inhibitors (ACEs inhibitors) or Angiotensin II Receptor Blockers (ARBs) in a real-life clinical trial in treatment of post-AMI patients with reduced left ventricular (LV) systolic function.

Clinical Trial Description

Background and study rationale: Sacubitril/Valsartan (SAC/VAL) is now approved by the U.S. Food and Drug Administration (FDA) for heart failure with reduced ejection fraction (HFrEF) and also, recently indicated as class I indication, level of evidence B in the European Society of Cardiology (ESC) guidelines 2016 on congestive heart failure (CHF).(1) PARADIGM-HF trial demonstrated that morbidity and mortality can be improved with SAC/VAL In comparison to enalapril, it reduced the occurrence of cardiovascular death or hospitalization for CHF by 20% with a 16% reduction in all-cause mortality.(2) So far, no available data about the effect of usage of SAC/VAL in post-AMI except in animal experimental models that proved efficacy of SAC/VAL in preventing AMI-induced LV dysfunction compared with SAC/VAL, also significantly attenuated LV scar size following AMI compared with placebo .(3) Aim of the work: - This study aims to investigate the effects of SAC/VAL in post-AMI through using it instead of conventional Angiotensin Converting enzyme inhibitors (ACEs inhibitors) or Angiotensin II Receptor Blockers (ARBs) in treatment of post-AMI patients with reduced left ventricular (LV) systolic function. - Design: Randomized open label interventional clinical trial. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03893435
Study type	Interventional
Source	The Young Investigator Group of Cardiovascular Research
Contact
Status	Completed
Phase	N/A
Start date	December 1, 2018
Completion date	October 1, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04451967` - Acute Myocardial Infarction Study in Northeastern China
Completed	`NCT05974397` - Nationwide Trends in Incidence, Healthcare Utilization, and Mortality in Hospitalized Acute Myocardial Infarction Patients in Taiwan
Not yet recruiting	`NCT04072081` - Drug-coated Balloon Versus Drug-eluting Stent in the Treatment of Coronary Artery Lesions in STEMI Patients in De Novo Coronary Lesions	N/A
Recruiting	`NCT03940443` - Differences in Mortality and Morbidity in Patients Suffering a Time-critical Condition Between GEMS and HEMS
Recruiting	`NCT03707626` - Collateral Circulation to LAD and Wellens Sign
Active, not recruiting	`NCT02669810` - EXCELLENT (EXpanded CELL ENdocardiac Transplantation)	Phase 2
Not yet recruiting	`NCT04104048` - Short Term Outcome of Primary Precutaneous Coronary Intervention in Ostial Versus Non Ostial Culprit Proximal Left Anterior Descending Artery Acute Myocardial Infraction
Active, not recruiting	`NCT02915107` - The SORT OUT IX STEMI OCT Trial	N/A
Completed	`NCT02896543` - The Relationship of Change of Dendritic Cells Fractalkine and P-selectin Patients With Acute Myocardial Infarction	N/A
Completed	`NCT02490969` - Copeptin Registry (proCORE) Biomarkers in Cardiology (BIC)-19	N/A
Completed	`NCT02531165` - Platelet Inhibition After Pre-hospital Ticagrelor Using Fentanyl Compared to Morphine in Patients With ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention	N/A
Withdrawn	`NCT01901471` - Cyclosporine in Acute Myocardial Infarction Complicated by Cardiogenic Shock	Phase 2
Completed	`NCT02312336` - A Pilot Study of Transcoronary Myocardial Cooling	N/A
Recruiting	`NCT02071342` - Study of ABSORB Stent in Acute Myocardial Infarction	N/A
Completed	`NCT02070913` - COOL-AMI EU Case Series Clinical Study
Terminated	`NCT01972126` - MAGNetic QRS-Fragmentation in Patients With Myocardial InfarcTion and Moderately RedUceD Ejection Fraction	N/A
Completed	`NCT01216995` - Safety and Efficacy of Adipose Derived Regenerative Cells (ADRCs) Delivered Via the Intracoronary Route in the Treatment of Patients With ST-elevation Acute Myocardial Infarction (AMI)	Phase 2
Completed	`NCT01887080` - Effects of Microcurrent in a Cardiovascular Rehabilitation Home-based Program	N/A
Withdrawn	`NCT01678339` - Sicilian Administrative Data Base Study in Acute Coronary Syndrome Patients	N/A
Completed	`NCT01627457` - Heart Cycle Prestudy	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

The Role of Sacubitril/Valsartan in Post-acute Myocardial Infarction — RSVP-AMI

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms